Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $901000.0.

  • X4 Pharmaceuticals' Interest & Investment Income fell 5184.39% to $901000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 3512.7%. This contributed to the annual value of $5.8 million for FY2024, which is 2590.57% up from last year.
  • X4 Pharmaceuticals' Interest & Investment Income amounted to $901000.0 in Q3 2025, which was down 5184.39% from $665000.0 recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Interest & Investment Income peaked at $1.9 million during Q3 2024, and registered a low of $2000.0 during Q1 2021.
  • Over the past 5 years, X4 Pharmaceuticals' median Interest & Investment Income value was $835000.0 (recorded in 2023), while the average stood at $693210.5.
  • In the last 5 years, X4 Pharmaceuticals' Interest & Investment Income crashed by 9932.43% in 2021 and then surged by 2773333.33% in 2023.
  • Over the past 5 years, X4 Pharmaceuticals' Interest & Investment Income (Quarter) stood at $3000.0 in 2021, then surged by 6500.0% to $198000.0 in 2022, then soared by 629.8% to $1.4 million in 2023, then dropped by 12.32% to $1.3 million in 2024, then decreased by 28.89% to $901000.0 in 2025.
  • Its Interest & Investment Income stands at $901000.0 for Q3 2025, versus $665000.0 for Q2 2025 and $1.0 million for Q1 2025.